Dianthus Therapeutics (DNTH) Assets Average (2018 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Assets Average of $554.2 million for Q4 2025, up 52.19% year-over-year from $364.1 million in Q4 2024, and up 22.67% quarter-over-quarter from $451.8 million in Q3 2025.
Dianthus Therapeutics (DNTH) Assets Average (2018 - 2025) Analysis & Trends
Dianthus Therapeutics' Assets Average history runs 8 years deep, the most recent figure standing at $554.2 million for Q4 2025.
- In Q4 2025, Assets Average rose 52.19% year-over-year to $554.2 million; the TTM figure through Dec 2025 stood at $554.2 million (up 52.19% YoY), while the FY2025 annual figure was $452.5 million, up 63.52% from the prior year.
- Assets Average for Q4 2025 stood at $554.2 million, up from $451.8 million in the prior quarter.
- The five-year high for Assets Average was $554.2 million in Q4 2025, with the low at $81.0 million in Q2 2023.
- The 5-year median for Assets Average is $195.1 million (2021), against an average of $249.5 million.
- The sharpest annual moves came in 2023 and 2024: Assets Average slumped 56.66% in 2023, then jumped 363.61% in 2024.
- Dianthus Therapeutics' Assets Average stood at $198.1 million in 2021, then plunged by 37.59% to $123.6 million in 2022, then soared by 50.41% to $185.9 million in 2023, then soared by 95.84% to $364.1 million in 2024, then jumped by 52.19% to $554.2 million in 2025.
- Business Quant data shows DNTH's Assets Average at $554.2 million in Q4 2025, $451.8 million in Q3 2025, and $337.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | 554.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 554.18 Mn |
| Sep 30, 2025 | 451.76 Mn |
| Jun 30, 2025 | 337.33 Mn |
| Mar 31, 2025 | 361.29 Mn |
| Dec 31, 2024 | 364.13 Mn |
| Sep 30, 2024 | 361.60 Mn |
| Jun 30, 2024 | 375.71 Mn |
| Mar 31, 2024 | 280.93 Mn |
| Dec 31, 2023 | 185.93 Mn |
| Sep 30, 2023 | 135.55 Mn |
| Jun 30, 2023 | 81.04 Mn |
| Mar 31, 2023 | 83.28 Mn |
| Dec 31, 2022 | 123.62 Mn |
| Sep 30, 2022 | 169.62 Mn |
| Jun 30, 2022 | 184.75 Mn |
| Mar 31, 2022 | 192.16 Mn |
| Dec 31, 2021 | 198.09 Mn |
| Sep 30, 2021 | 213.31 Mn |
| Jun 30, 2021 | 182.50 Mn |
| Mar 31, 2021 | 153.12 Mn |